The company was recognized for its research and development activities that improve its customers’ return on investment in ingredients such as BioCell Collagen II.
Bone- and joint-health ingredient specialist BioCell Technology LLC (Newport Beach, CA) received Frost & Sullivan’s 2010 North American Customer Value Enhancement of the Year Award in bone- and joint-health ingredients. The company was recognized for its research and development activities that improve its customers’ return on investment in ingredients such as BioCell Collagen II.
“BioCell Technology has proven consistently to be a significant contender in a market that has been dominated by glucosamine/chondroitin products,” says Suhail Ishaq, BioCell’s vice president of technology. “In light of the recent negative research publications questioning their efficacy, consumers are looking for more effective options that deliver more reliable results. BioCell Collagen II has unique differentiated properties and is supported by substantial clinical data that conclusively prove the effectiveness of the product for joint health.”
The company recently completed its largest-ever human clinical trial on BioCell Collagen II, which demonstrated efficacy and safe long-term use in 80 patients with osteoarthritis symptoms. The ingredient was also recently affirmed GRAS for use in food and beverages.
The Frost & Sullivan award also recognized BioCell’s “right combination of supporting clinical data and a cobranding strategy,” said Frost & Sullivan senior research analyst Kaushik Ramakrishnan. “This is augmented by their strong IP protection, which ensures a long-term and delightful relationship with clients and consumers.”